AstraZeneca(US:AZN) ZACKSยท2025-04-24 14:20Core Insights - Astrazeneca (AZN) is projected to report quarterly earnings of $1.10 per share, a 6.8% increase year-over-year, with revenues expected to reach $13.68 billion, reflecting a 7.9% year-over-year growth [1] Earnings Projections - There have been no revisions in the consensus EPS estimate for the quarter over the last 30 days, indicating stability in analysts' forecasts [1] - Changes in earnings projections are crucial for predicting investor reactions, as empirical studies show a strong correlation between earnings estimate trends and short-term stock price movements [2] Key Metrics Estimates - Analysts predict 'BioPharmaceuticals- CVRM- Crestor- World' will reach $294.03 million, a -1% change year-over-year [4] - The estimate for 'BioPharmaceuticals- CVRM- Seloken/Toprol-XL- World' is $154.45 million, indicating a -6.4% change [4] - 'Oncology- Zoladex- World' is estimated at $268.24 million, reflecting a -2.8% change [4] Additional Product Estimates - 'Oncology- Tagrisso- World' is expected to reach $1.67 billion, a +4.6% change year-over-year [5] - The consensus for 'BioPharmaceuticals- CVRM- Crestor- U.S.' stands at $8.31 million, indicating a -16.9% change [5] - 'Other Medicines- Nexium- U.S.' is projected at $19.28 million, suggesting a -12.4% change [5] Further Product Insights - 'BioPharmaceuticals- R&I- Fasenra- U.S.' is forecasted to reach $220.22 million, a +4.9% change [6] - 'BioPharmaceuticals- CVRM- Brilinta- U.S.' is estimated at $133.59 million, indicating an -18% change [6] - 'Oncology- Lynparza- U.S.' is projected at $302.67 million, reflecting a +5.1% change [6] Oncology Product Forecasts - 'Oncology- Imfinzi- U.S.' is expected to come in at $719.14 million, a +23.6% change year-over-year [7] - 'Oncology- Calquence- U.S.' is projected at $493.39 million, indicating a -0.1% change [7] - 'BioPharmaceuticals- CVRM- Farxiga- U.S.' is estimated to reach $489.15 million, reflecting a +3% change [7] Stock Performance - Astrazeneca shares have decreased by -5.8% over the past month, compared to a -5.1% change in the Zacks S&P 500 composite [8] - With a Zacks Rank 3 (Hold), AZN is expected to perform in line with the overall market in the near future [8]